OSTX Stock Overview
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
OS Therapies Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.22 |
| 52 Week High | US$4.90 |
| 52 Week Low | US$2.51 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 68.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| OSTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.5% | -1.0% | 0.2% |
| 1Y | n/a | 9.7% | 17.6% |
Return vs Industry: Insufficient data to determine how OSTX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how OSTX performed against the US Market.
Price Volatility
| OSTX volatility | |
|---|---|
| OSTX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: OSTX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine OSTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 4 | Paul Romness | ostherapies.com |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OS Therapies Incorporated Fundamentals Summary
| OSTX fundamental statistics | |
|---|---|
| Market cap | US$84.61m |
| Earnings (TTM) | -US$7.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.2x
P/E RatioIs OSTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$5.15k |
| Gross Profit | -US$5.15k |
| Other Expenses | US$7.52m |
| Earnings | -US$7.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -61.0% |
How did OSTX perform over the long term?
See historical performance and comparison